
Global report - August 23, 2016
Pfizer to acquire Medivation
Pfizer and Medivation has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have […]

Acquisition - April 19, 2016
AZ explore potential takeover of Medivation
The Sunday Times reports that AstraZeneca has held “internal talks” regarding a potential bid for Medivation, but the company has not yet made a formal proposal, reported the magazine and citing unnamed sources. According to the newspaper, AstraZeneca has been tracking Medivation for the past six months, while a senior healthcare banker is quoted as saying […]